Stock Analysis
- Poland
- /
- Healthcare Services
- /
- WSE:NEU
NEUCA Third Quarter 2024 Earnings: EPS: zł9.36 (vs zł10.28 in 3Q 2023)
NEUCA (WSE:NEU) Third Quarter 2024 Results
Key Financial Results
- Revenue: zł3.19b (up 7.3% from 3Q 2023).
- Net income: zł41.9m (down 7.1% from 3Q 2023).
- Profit margin: 1.3% (down from 1.5% in 3Q 2023). The decrease in margin was driven by higher expenses.
- EPS: zł9.36 (down from zł10.28 in 3Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
NEUCA Earnings Insights
Looking ahead, revenue is forecast to grow 4.4% p.a. on average during the next 3 years, compared to a 5.1% growth forecast for the Healthcare industry in Europe.
Performance of the market in Poland.
The company's shares are down 2.5% from a week ago.
Risk Analysis
Be aware that NEUCA is showing 1 warning sign in our investment analysis that you should know about...
Valuation is complex, but we're here to simplify it.
Discover if NEUCA might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About WSE:NEU
NEUCA
Engages in the wholesale distribution of pharmaceuticals in Poland.